Here are the 424B prospectus supplements from Catheter Precision, Inc. (VTAK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VTAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTAK filings page.
Catheter Precision, Inc. (symbol: VTAK) is the issuer of record for a Form 424B3 filing submitted to the SEC.
Catheter Precision, Inc. is registering 68,067,042 shares of Common Stock for resale by existing holders, including shares issuable from multiple series of convertible preferred stock and warrants. The company will not receive any proceeds from these sales, though it will bear registration expenses.
The capital structure includes Series C-1, C-2, C-3, C-4 and D preferred stock with variable conversion prices tied to trading levels, a large potential Series C-4 facility, related‑party Series J preferred stock and Series M warrants, all convertible into Common Stock subject to ownership limits and floor-price conditions. As of July 10, 2026, 3,609,471 Common shares were outstanding, and the prospectus warns that full issuance of registered conversion shares could cause substantial dilution for current stockholders.
Catheter operates two segments: cardiac electrophysiology, built around its VIVO mapping system and LockeT suture retention device, and a newer private aviation platform acquired through FLYTE and Ponderosa Air, which generated approximately $0.2 million of revenue for the quarter ended March 31, 2026. The company reports limited cash, a significant working capital deficit and a going‑concern warning, and plans to use earlier private‑placement proceeds mainly to repay debt, restructure legacy catheter operations and simplify its balance sheet.